Research & Development
Brand Institute works with Myovant Sciences on developing brand name ORGOVYX for advanced hormone-sensitive prostate cancer treatment
20 June 2022 -

Brand Institute, a company involved in pharmaceutical and healthcare-related name development, announced on Friday that it has worked with United Kingdom-based Myovant Sciences for the development of the brand name ORGOVYX (relugolix), for an oral medication intended to treat adult patients with advanced hormone-sensitive prostate cancer.

Myovant Sciences developed the product, which it said is the first and only oral androgen deprivation therapy offered in Europe intended to treat advanced hormone-sensitive prostate cancer.

The European Commission (EC) has granted marketing authorisation for the product in all member states of the European Union, Iceland, Lichtenstein, and Norway. The product received US Food and Drug Administration (FDA) approval to treat adult patients with advanced prostate cancer in December 2020.



Related Headlines